Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Being mildly overweight benefits ALS patients

Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, Massachusetts General Hospital researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

12 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

'Bad cholesterol' needed to gain more muscle mass

The so-called "bad cholesterol" - low-density lipoprotein commonly called LDL - may not be so bad after all, shows a Texas A&M University study that casts new light on the cholesterol debate, particularly among adults who exercise.

6 May 2011

Study examines racial differences between obesity and vitamin D among children

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that while black and white children with vitamin D deficiency both had higher fat levels, black children were more likely to have higher levels of fat just under their skin and white children were more likely to have higher levels of fat between their internal organs.

28 Apr 2011

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

There's no question, drugs work in treating disease. But can they work better, and safer?

22 Apr 2011

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

Computational modeling provides more knowledge of lipoprotein properties

Computational modeling increases our knowledge of lipoprotein properties that cannot be measured using experimental methods. Lipoproteins are particles that transport cholesterol in our bloodstream. According to the doctoral dissertation of Master of Science in Technology Linda Kumpula (Aalto University School of Science), the differences in the composition, size and number of lipoprotein particles transporting cholesterol in individuals can be computationally modeled using experimental data.

8 Apr 2011

LDL particles may be a more accurate measure of subclinical atherosclerosis than LDL cholesterol

LipoScience, Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance (NMR) technology, today announced presentations of two clinical studies "from the podium" at the 60th Annual Scientific Session of the American College of Cardiology.

6 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Routine periodic fasting can reduce risk of coronary heart disease

Fasting has long been associated with religious rituals, diets, and political protests. Now new evidence from cardiac researchers at the Intermountain Medical Center Heart Institute demonstrates that routine periodic fasting is also good for your health, and your heart.

4 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Candy consumption can help reduce weight and risk of CVD

Good news for candy and chocolate lovers: they tend to weigh less, have lower body mass indices and waist circumferences, and have decreased levels of risk factors for cardiovascular disease and metabolic syndrome, according to a new study published in Nutrition Research.

31 Mar 2011

20-year data shows bariatric surgery to reduce risk of heart attack and stroke in diabetics

In the longest study of its kind, bariatric surgery has been shown to reduce the risk of heart attack and stroke in patients with diabetes. These results and other groundbreaking research were presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes, hosted by NewYork-Presbyterian Hospital and Weill Cornell Medical College.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Journal of Clinical Lipidology publishes LipoScience LDL particle study results against CVD

LipoScience, Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance technology, today announced publication of a clinical study in the Journal of Clinical Lipidology demonstrating that in many people, low density lipoprotein cholesterol is a less accurate predictor of cardiovascular disease events than LDL particle number.

19 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

Vitamin A may play key role in sperm cell formation and development of central nervous system

In a recently-published study mapping the structure and function of the so-called "orphan" nuclear receptor TR4, Van Andel Research Institute (VARI) investigators suggest that Vitamin A may play a more direct role than was previously known in certain physiological functions including sperm cell formation and the development of the central nervous system.

18 Mar 2011

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

16 Mar 2011

Human growth, height, size: Reasons to be small

Almost everybody these days thinks that it is best to be tall, meaning much taller than the average traditional height of Asian populations, and even taller than the current average height of populations in high-income countries. It is also often believed – though people might be shy to admit this – that tall people are intrinsically superior to short people. The expressions 'look up to' and 'look down on' are significant.

15 Mar 2011

Lipoprotein News and Research

Further Reading

Being mildly overweight benefits ALS patients

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

'Bad cholesterol' needed to gain more muscle mass

Study examines racial differences between obesity and vitamin D among children

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Computational modeling provides more knowledge of lipoprotein properties

LDL particles may be a more accurate measure of subclinical atherosclerosis than LDL cholesterol

TZDs might serve as new agents for addiction treatment

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Routine periodic fasting can reduce risk of coronary heart disease

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

Candy consumption can help reduce weight and risk of CVD

20-year data shows bariatric surgery to reduce risk of heart attack and stroke in diabetics

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Journal of Clinical Lipidology publishes LipoScience LDL particle study results against CVD

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Vitamin A may play key role in sperm cell formation and development of central nervous system

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

Human growth, height, size: Reasons to be small

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News